Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone760-931-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$507.67 million
Profitability
Miscellaneous
Employees547
OptionableOptionable
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.10. The firm earned $145.40 million during the quarter, compared to the consensus estimate of $146.77 million. Ionis Pharmaceuticals had a negative return on equity of 1.58% and a negative net margin of 7.52%. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.02) earnings per share. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What price target have analysts set for IONS?
7 equities research analysts have issued 1-year target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $46.00 to $75.00. On average, they expect Ionis Pharmaceuticals' share price to reach $53.7143 in the next twelve months. This suggests that the stock has a possible downside of 7.4%. View Analyst Price Targets for Ionis Pharmaceuticals.
What is the consensus analysts' recommendation for Ionis Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.
Has Ionis Pharmaceuticals been receiving favorable news coverage?
Media coverage about IONS stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY) and Sarepta Therapeutics (SRPT).
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 74)
- Dr. Brett P. Monia, Founder, COO & Sr. VP of Translational Medicine (Age 58)
- Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 57)
- Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 61)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)
Who are Ionis Pharmaceuticals' major shareholders?
Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.27%), Peregrine Capital Management LLC (0.19%), BLB&B Advisors LLC (0.18%) and First Hawaiian Bank (0.00%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Which institutional investors are selling Ionis Pharmaceuticals stock?
IONS stock was sold by a variety of institutional investors in the last quarter, including BLB&B Advisors LLC, Peregrine Capital Management LLC and First Hawaiian Bank. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Which institutional investors are buying Ionis Pharmaceuticals stock?
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $58.03.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $7.92 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.
What is Ionis Pharmaceuticals' official website?
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
